PDF(Pubmed)
Abstract：
ECD is considered to have rapid progression and poor prognosis. Studies have shown that vemurafenib is effective for ECD patients with orbital involvement, but not for ECD with multiple organs. The refinement of treatment approaches and the increased awareness of ECD have led to a dramatic improvement in prognosis.
摘要：
认为ECD具有快速进展和不良预后。研究表明，vemurafenib对眼眶受累的ECD患者有效，但不适用于具有多个器官的ECD。治疗方法的完善和对ECD的认识的提高导致预后的显着改善。
